默克周虹离任，加入诺和诺德

Core Insights - Novo Nordisk's current Executive Vice President of Product and Portfolio Strategy, Ludovic Helfgott, is leaving the company to pursue new opportunities [1] - Hong Chow, former Global Executive Vice President of Merck Pharmaceuticals and head of China and International Markets, will succeed Helfgott in the role [1] Company Transition - The leadership change at Novo Nordisk indicates a strategic shift as the company prepares for future challenges and opportunities in the pharmaceutical industry [1] - The appointment of Hong Chow, with her extensive experience in international markets, may enhance Novo Nordisk's global strategy and market presence [1]